Event Schedule
Have a look at Schedule
Day 1: Innovations in Early Drug Discovery & Technologies
8:00
Bright Start
Registration + Coffee With Impactful Investors
8:50
Chair Welcome Address
Soroush Safaei
Senior Principal Scientist, Sanofi
9:00
Keynote Session
Neuroscience Drug Discovery – Where is the Innovative Biology Coming From and What Do We Miss?
Johan Luthman
EVP & Head of R&D, Lundbeck
Target Identification & Hit Discovery
9:20
Talk 1
Human-Centric Target Discovery Leveraging In Vitro & In Silico Models
Jakob E. Larsen
Target Discovery Director, Novo Nordisk
9:40
Partner Slot 1
Smarter Together? Advancing Predictive Data Analytics Tools in Target ID & Validation
Joelle Gola
Senior Application Scientist, CAS - a division of the American Chemical Society
10:00
Featured Presentation
Harnessing Genetic Resilience: A New Paradigm for Target Discovery with GenMor-AI
David Bearss
CEO, Halia Therapeutics
10:20
Coffee Break & Networking Session
AI & Automation in Drug Discovery-I
11:10
Talk 2
Accelerating and Scaling Machine Learning for Enhanced Integration and Decision-Making in Roche's Drug Discovery Pipeline
 Mu.webp)
Le (Muller) Mu
MLOps Product Owner, Roche
11:30
Partner Slot 2
Advancing Cancer Biomarkers and Antiviral Research
Dr Joseph Lackey
Technical Manager, LGC Standards
11:55
Talk 3
GenAI Meets RWD: Building a Multi-Agent GenAI Platform for RWD/RWE & Insight
 Choudhary.webp)
Abhishek (ABC) Choudhary
Principal Data Engineer, Bayer
12:15
Talk 4
What Progress Have We Made in AI-Augmented Drug Discovery?
Aisyah Sjöholm
Associate Director, Insilico Medicine
12:35
Lunch Break & One-on-One Meetings
Strategies for Addressing ‘Undruggable’ Targets
13:35
Keynote Presentation
Fast-Tracking Drug Discovery: Innovative Modalities and Strategies for Unlocking High-Value Targets
Stefan Geschwindner
Director Biophysics, AstraZeneca
14:05
Partner Slot 3
An Integrated Screening Strategy to Evaluate the Therapeutic Potential of Both Peptide and Non-peptide GLP-1 RAs in Preclinical Metabolic Models
Sumit Chaudhary
Director, In Vivo Pharmacology, Sai Life Sciences
14:25
Talk 5
The Role of Protein Dynamics in Targeted Protein Degradation
Radoslav Enchev
Group Leader, The Francis Crick Institute
14:45
Partner Slot 4
Digital Chemistry Offering at Merck, Covering the Workflow from Drug Discovery to Synthesis to Sourcing of Chemical Libraries
Angelo Lanzilotto
Solution Sales Specialist - Digital Chemistry, Merck KGaA
Innovations in Medicinal Chemistry
14:55
Keynote Presentation
ATM Kinase Inhibitor Lartesertib: A Pioneering Application of Atropisomerism in Drug Design
Dr. Thomas Fuchss
Director Medicinal Chemistry, Merck
15:15
Partner Slot 5
From Edits To Insights - How Custom CRISPR Cell Models are Rewriting Drug Discovery
Zofia Świątczak
Head of Sales - Europe, EditCo
15:35
Coffee Break & Networking Session
16:25
Talk 6
Novel Chemical Modalities: Expanding Drug Space Beyond Traditional Molecules
Sonia Novo
Principal Scientist, UCB
16:45
Talk 7
Best-in-Class Oligonucleotide Therapeutics to Expand the Universe of Druggable Targets
Frank Jaschinski
CSO, Secarna Pharmaceuticals
17:05
Happy Hour Session (45-Minutes)
Day 2: Advancing Drug Discovery Through Biologics and New Therapeutic Modalities
8:00
Bright Start
Registration + Coffee With Impactful Investors
8:50
Chair Welcome Address
Soroush Safaei
Senior Principal Scientist, Sanofi
9:00
Featured Talk
New Trends in Complex Cell Models
David Moreno Delgado
Director, UCB
AI & Automation in Drug Discovery-II
9:20
Talk 1
Transforming Drug Discovery: Generative Models and Electrostatic Complementarity
Rinaldo Montalvão
Director AI, Gain Therapeutics
9:40
Featured Talk
Predicting Drug Efficacy in Virtual Patients
Philippe Moingeon
Adj. Professor, AI in Health, Université Paris-Saclay
10:00
Talk 2
Identification and Validation of Pharmacological Non-Coding Targets
Alessandro Bonetti
Director Neuroscience, AstraZeneca
10:20
Business Card Exchange: Coffee Break
Translational Medicine & Personalized Therapeutics
11:10
Keynote Presentation
Precision Medicine 2.0: Harnessing the Oncobiome for Personalized Cancer Therapy
Rafik Fellague-Chebra
Global Medical Director, Novartis Oncology
11:40
Talk 3
QUANTROseq®, a Transcriptomic Based Drug Discovery Platform for Transcription Factors and Cell Signaling Regulators
Arianna Sabò
Head of Research, Quantro Therapeutics
12:00
Case Study
From Vision to Impact: AOP Health's 30-Year Journey in Rare Diseases and the Road Ahead
Carmen Visus
Sr. Director, R&D Ops, AOP Health
12:30
Lead Generation Luncheon
13:30
Startup Investor Panel
What Investors Want in Early-Stage Biotech
Moderator
Jason Mellad
CEO, Start Codon
Panellists
Gemma Guinart Mola
Principal, Invivo Partners
Thomas Harth
Partner, Ysios Capital
Daniel Rooke
Co-Founder and Strategic Advisor, Start Codon
14:10
Coffee Break & Networking Session
15:00
Keynote Presentation
Hot-Melt Extrusion (HME): A Cost-effective Approach to Enhancing Bioavailability
Dr. Devendra Ridhurkar
Founder and CEO, RidNova
15:20
Talk 4
JJP-1008: Anti-CD270 Antibody Checkpoint Inhibitor for Cancer Treatment: Swing Around Patient’s CD270 Immunosuppressive Disadvantage
Tomasz Sitar
Head of CMC, JJP Biologics
15:40
Interactive Panel
Turning the Tide on Undruggable Targets: Emerging Modalities
Moderator
Soroush Safaei
Senior Principal Scientist, Sanofi
Panellists
Heena Khatter
Principal Scientist, Roche
Pascal Benderitter
Head of Medicinal Chemistry, QUANTRO Therapeutics GmbH
Stefan Geschwindner
Director Biophysics, AstraZeneca
16:20
Final Remarks
Soroush Safaei
Senior Principal Scientist, Sanofi
16:30
